I ran into Virginia Acha last week at the NESTA event in London, but she didn’t tell me about this!
Derek Lowe at In the Pipeline notes that Pfizer is apparently allowing external companies to screen against their internal library.
But I’m told that Pfizer has been meeting with several other (mostly smaller) companies, offering their (entire?) compound library as a screening resource. As I understand it, you need to come to them with a reasonably formatted HTS assay, and there’s a fee in the high hundreds of thousands to run the screen.
This isn’t all the way towards open innovation. In a true open innovation sense, the fees and the barriers would be lower, as the goal would be to maximize dealflow. But that probably means, as Derek also notes, that the IP issues aren’t settled.
Should anyone involved want to talk about how to settle those issues, we’d be interested in hearing about how this process is working out.